These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 11900310)
21. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987 [TBL] [Abstract][Full Text] [Related]
22. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. Mazumder MK; Choudhury S Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161 [TBL] [Abstract][Full Text] [Related]
23. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Nordberg A; Ballard C; Bullock R; Darreh-Shori T; Somogyi M Prim Care Companion CNS Disord; 2013; 15(2):. PubMed ID: 23930233 [TBL] [Abstract][Full Text] [Related]
24. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of antioxidant peptides obtained from enzymatic pea protein hydrolysates and their ultrafiltration peptide fractions. Asen ND; Aluko RE J Food Biochem; 2022 Nov; 46(11):e14289. PubMed ID: 35758753 [TBL] [Abstract][Full Text] [Related]
25. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment. Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176 [TBL] [Abstract][Full Text] [Related]
26. Cholinesterase inhibitors: new roles and therapeutic alternatives. Giacobini E Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240 [TBL] [Abstract][Full Text] [Related]
27. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017. Andrisano V; Naldi M; De Simone A; Bartolini M Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691 [TBL] [Abstract][Full Text] [Related]
28. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase. Petzer A; Harvey BH; Petzer JP Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345 [TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin. Kumar S Indian J Pharmacol; 2015; 47(4):444-6. PubMed ID: 26288480 [TBL] [Abstract][Full Text] [Related]
30. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845 [TBL] [Abstract][Full Text] [Related]
31. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives. Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344 [TBL] [Abstract][Full Text] [Related]
32. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Bullock R Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828 [TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease. Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948 [TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase. Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700 [TBL] [Abstract][Full Text] [Related]
35. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. Pacheco G; Palacios-Esquivel R; Moss DE J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741 [TBL] [Abstract][Full Text] [Related]
36. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease. Okello EJ; Mather J Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457 [TBL] [Abstract][Full Text] [Related]
37. Synthesis of indole derivatives as Alzheimer inhibitors and their molecular docking study. Homoud ZA; Taha M; Rahim F; Iqbal N; Nawaz M; Farooq RK; Wadood A; Alomari M; Islam I; Algheribe S; Rehman AU; Khan KM; Uddin N J Biomol Struct Dyn; 2023 Nov; 41(19):9865-9878. PubMed ID: 36404604 [TBL] [Abstract][Full Text] [Related]
38. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Poirier J Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368 [TBL] [Abstract][Full Text] [Related]
39. Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus Dos Santos R; Morais-Urano RP; Marçal RM; Silva GH; Santos MFC Nat Prod Res; 2022 Aug; 36(16):4153-4158. PubMed ID: 34498969 [TBL] [Abstract][Full Text] [Related]
40. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease]. Patocka J; Strunecká A; Rípová D Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]